757 related articles for article (PubMed ID: 20205482)
41. Dapagliflozin (SGLT2-i) induced euglycaemic diabetic ketoacidosis.
Leader R; Cowen J; Rajeev SP
BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31537607
[TBL] [Abstract][Full Text] [Related]
42. Dapagliflozin for the treatment of type 2 diabetes.
Brooks AM; Thacker SM
Ann Pharmacother; 2009 Jul; 43(7):1286-93. PubMed ID: 19584379
[TBL] [Abstract][Full Text] [Related]
43. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
44. Sodium-glucose co-transporter 2 inhibition in diabetes treatment: current evidence and future perspectives.
Rizos EC; Elisaf MS
Curr Pharm Des; 2014; 20(22):3647-56. PubMed ID: 24040872
[TBL] [Abstract][Full Text] [Related]
45. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.
Komoroski B; Vachharajani N; Boulton D; Kornhauser D; Geraldes M; Li L; Pfister M
Clin Pharmacol Ther; 2009 May; 85(5):520-6. PubMed ID: 19129748
[TBL] [Abstract][Full Text] [Related]
46. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
Carlson CJ; Santamarina ML
Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
[TBL] [Abstract][Full Text] [Related]
48. Dapagliflozin Binds Specifically to Sodium-Glucose Cotransporter 2 in the Proximal Renal Tubule.
Ghezzi C; Yu AS; Hirayama BA; Kepe V; Liu J; Scafoglio C; Powell DR; Huang SC; Satyamurthy N; Barrio JR; Wright EM
J Am Soc Nephrol; 2017 Mar; 28(3):802-810. PubMed ID: 27620988
[TBL] [Abstract][Full Text] [Related]
49. Ramping glucosuria for management of type 2 diabetes mellitus: an emerging cynosure.
Malla P; Kumar R; Mahapatra MK; Kumar M
Med Res Rev; 2014 Nov; 34(6):1146-67. PubMed ID: 24633706
[TBL] [Abstract][Full Text] [Related]
50. [Role of the kidneys in glucose homeostasis. Implication of sodium-glucose cotransporter 2 (SGLT2) in diabetes mellitus treatment].
Girard J
Nephrol Ther; 2017 Apr; 13 Suppl 1():S35-S41. PubMed ID: 28577741
[TBL] [Abstract][Full Text] [Related]
51. Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?
Petrykiv S; Laverman GD; de Zeeuw D; Heerspink HJL
Diabetes Obes Metab; 2018 Jan; 20(1):224-227. PubMed ID: 28685934
[TBL] [Abstract][Full Text] [Related]
52. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects.
Yang L; Li H; Li H; Bui A; Chang M; Liu X; Kasichayanula S; Griffen SC; Lacreta FP; Boulton DW
Clin Ther; 2013 Aug; 35(8):1211-1222.e2. PubMed ID: 23910664
[TBL] [Abstract][Full Text] [Related]
54. The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors.
Weir MR
Postgrad Med; 2016; 128(3):290-8. PubMed ID: 26821720
[TBL] [Abstract][Full Text] [Related]
55. SGLT2 inhibitors.
Dardi I; Kouvatsos T; Jabbour SA
Biochem Pharmacol; 2016 Feb; 101():27-39. PubMed ID: 26362302
[TBL] [Abstract][Full Text] [Related]
56. Sodium glucose cotransporter 2 and the diabetic kidney.
Komala MG; Panchapakesan U; Pollock C; Mather A
Curr Opin Nephrol Hypertens; 2013 Jan; 22(1):113-9. PubMed ID: 23042029
[TBL] [Abstract][Full Text] [Related]
57. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.
Komoroski B; Vachharajani N; Feng Y; Li L; Kornhauser D; Pfister M
Clin Pharmacol Ther; 2009 May; 85(5):513-9. PubMed ID: 19129749
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Scheen AJ
Clin Pharmacokinet; 2015 Jul; 54(7):691-708. PubMed ID: 25805666
[TBL] [Abstract][Full Text] [Related]
59. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans.
List JF; Whaley JM
Kidney Int Suppl; 2011 Mar; (120):S20-7. PubMed ID: 21358698
[TBL] [Abstract][Full Text] [Related]
60. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.
Schwartz SL; Akinlade B; Klasen S; Kowalski D; Zhang W; Wilpshaar W
Diabetes Technol Ther; 2011 Dec; 13(12):1219-27. PubMed ID: 21854192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]